Efficacy of sequential therapy in eradication of Helicobacter Pylori

Comparison of two Sequential therapy regimens and Standard Triple-Drug therapy for eradication of Helicobacter Pylori in patients with Dyspepsia

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015082323736N1

Enrollment

300

Registered

2016-02-09

Start date

2016-01-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Dyspepsia. Condition 2: Helicobacter pylori. Dyspepsia Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Intervention 3 (Control group): Standard triple therapy with Omeprazole 20 mg capsule twice a day, Amoxicillin 1 g capsule twice a day and Clarithromycin 500 mg capsule twice a day for

Treatment - Drugs

Intervention 3 (Control group): Standard triple therapy with Omeprazole 20 mg capsule twice a day, Amoxicillin 1 g capsule twice a day and Clarithromycin 500 mg capsule twice a day for 2 weeks

Intervention 1: The sequential regimen is including Omeprazole 20 mg capsule twice a day and Amoxicillin 1 g capsule twice a day for the first week and Omeprazole 20 mg capsule twice a day, Clarith

Intervention 2: The sequential regimen is including Omeprazole 20 mg capsule twice a day and Amoxicillin 1 g capsule twice a day for the first week and Omeprazole 20 mg capsule twice a day, Levoflo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with Dyspepsia for whom endoscopy was performed and those ones that have the positive Helicobacter Pylori infection based on pathology result and those who have not been treated for Helicobacter Pylori eradication before. Exclusion criteria: Patients that need more treatments based on endoscopy results, patients that have severe underling diseases (heart disease, kidney disease, liver disease, etc), pregnant and lactating women, patients who have allergies to drugs we want to use.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Eradication of Helicobacter Pylori. Timepoint: 6 weeks after the completion of treatment course. Method of measurement: (UBT) Urea Breath Test.	—

Secondary

Measure	Time frame
Side effects of drugs. Timepoint: 2 Weeks After Beginning of Treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMosayeb Moradniani

Lorstan University of Medical Sciences

dr.m.morad@lums.ac.ir+98 66 3341 1439

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026